Trial Profile
A phase I study to evaluate the safety, efficacy and pharmacokinetics of Proxalutamide (GT0918) in patients with advanced Castrate Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2020
Price :
$35
*
At a glance
- Drugs Pruxelutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- 24 May 2020 Results assessing safety, pharmacokinetics (PK) and antitumour effects of GT0918 in castration-resistant prostate cancer patients, published in the European Journal of Cancer.
- 16 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology